Medicines for Europe’s newly published position paper explores how the current design of procurement rules in EU Member States, often aimed exclusively at reducing costs, has led to the consolidation of supply and increased risks for supply security.
Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.
Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.
Medicines for Europe and the European Business Association (EBA) have jointly proposed strategic steps for the integration of Ukraine’s pharmaceutical industry into the European Union, which we believe can be implemented before Ukraine’s full accession to the EU. This initiative aligns with Ukraine’s candidacy for EU membership and aims to harmonize the country’s healthcare system and pharmaceutical market with EU standards.
Medicines for Europe is deeply concerned about the Extended Producer Responsibility (EPR) system in the Urban Wastewater Treatment Directive under discussion in trilogue negotiations.
By 2032, the biosimilar medicines contribution to health systems access and sustainability will soon match the impact of generic medicines. The number of biological medicines set to lose market exclusivity represents an opportunity for competition to free up invaluable resources for healthcare systems, to improve patient access and budget sustainability.
the continuous increase in the prices of input raw materials as well as the increase in the cost of production and transport of medicines are in direct contrast to the ongoing price reduction of generic and biosimilar drugs in the Slovak Republic. The consequence is a rising shortage of medicines for patients. Even a short interruption in the availability of medicines can have a major impact on a patient’s health and life. Every patient has a right to certain access to the medicines they need. This access is a fundamental aspect of providing quality healthcare.
Medicines for Europe, the European association representing generic, biosimilar and valued added medicines manufacturing, is writing to underline the key principles that we support in relation to the reform of EU pharmaceutical legislation which is currently under review in the European Parliament and the Council.
Medicines for Europe, representing the European value-added medicines industry, is calling for legislative reforms that will pave the way for patient access to safe, timely and affordable innovation for known medicines.
Medicines repurposing has emerged as an important strategy to address patients’ needs.
The EU is currently reviewing its Pharmaceutical Legislation, and the latest IQVIA white paper “Assessing the biosimilar void” sheds light on the growing biological medicines market and the opportunity to improve equitable access with biosimilar medicines competition.